LAKE OSWEGO, Ore., July 31, 2019 /PRNewswire/ — BIOTRONIK today announced the company’s PK Papyrus® covered coronary stent system1 has been named a finalist in the 2019 Prix Galien USA Awards Ceremony for Best Medical Technology. PK Papyrus is used in emergency situations to create a physical barrier to seal life-threatening perforated coronary arteries without the need for invasive surgery. In September […]
Coronary/Structural Heart
Reflow Medical Enrolls First Patients in DEEPER OUS Spur Stent Trial
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Reflow Medical, Inc. announces that the first patients have been enrolled in its DEEPER OUS clinical trial using the Temporary Spur Stent System. DEEPER OUS is a 100-patient prospective, non-randomized, multicenter trial designed to assess the safety and efficacy of the Temporary Spur Stent System compared to […]
Northeast Ohio Man Survives Extreme Cardiac Event, Receives 30+ Defibrillations
News Release Department of Marketing and Communications 11100 Euclid Avenue Cleveland, OH 44106 Northeast Ohio Man Survives Extreme Cardiac Event, Receives 30+ Defibrillations UH Geauga Medical Center team shows perseverance and expertise in incredible effort A Northeast Ohio man who experienced what likely would have been a deadly […]
Miracor Medical Starts PiCSO-AMI-I Randomized Study in EU
AWANS, Belgium–(BUSINESS WIRE)–Miracor Medical SA (Miracor Medical) today announced the initiation and first patient enrollment in the PICSO-AMI-I study to evaluate the benefits of PiCSO® therapy compared with conventional PCI for the treatment of anterior STEMI patients. The first patient enrolled into this study was treated at Oxford Heart Center, Oxford, […]
Ortho Receives CE Mark for Enhanced VITROS® Immunodiagnostic Products NT-proBNP II Assay, an Aid in Diagnosing and Assessing Heart Failure
RARITAN, N.J., July 23, 2019 /PRNewswire/ — Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced the CE Mark of an enhanced version of its VITROS® NT-proBNP II assay, part of Ortho’s expansive cardiac menu. The analytical characteristics and clinical performance of the VITROS NT-proBNP II assay allow clinicians to efficiently assess […]
SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent
TIANJIN, China, July 23, 2019 /PRNewswire/ — In a significant milestone toward obtaining key regulatory approvals for the BuMA Supreme Drug-Eluting Stent (DES) System, SINOMED has completed enrollment in the PIONEER III randomized, controlled clinical trial. The PIONEER III trial is designed to assess the safety and effectiveness of the BuMA Supreme […]
MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi
SOUTH SAN FRANCISCO, Calif., July 18, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today announced updates related to its hypertrophic cardiomyopathy (HCM) treatment portfolio, including lead therapeutic candidate, mavacamten. Patient screening has closed for the Phase 3 EXPLORER-HCM registrational clinical study to assess the effect of mavacamten in treating […]
New study finds both components of blood pressure predict heart attack, stroke risk
OAKLAND, Calif., July 17, 2019 /PRNewswire/ — Both numbers in a blood pressure reading — the “upper” systolic and the “lower” diastolic — independently predicted the risk of heart attack or stroke in a very large Kaiser Permanente study that included more than 36 million blood pressure readings from more than 1 […]
Corindus Adds Two New CorPath GRX Installations to HCA Healthcare Facilities
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it has installed CorPath® GRX Systems in two new hospitals affiliated with one of the nation’s largest hospital networks, HCA Healthcare. The new systems are now installed in hospital locations […]
Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative
SAN DIEGO, July 16, 2019 /PRNewswire/ — Ambrx Inc. today announced that Bristol-Myers Squibb Company (“BMS”) has initiated a phase I clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of long-acting Relaxin for the potential treatment of heart failure (“HF”). Long-acting Relaxin is an investigational biologic produced using Ambrx’ proprietary expanded genetic code […]



